HIERARCHICAL IMMUNOSUPPRESSION OF REGIONAL LYMPH-NODES IN PATIENTS WITH HEAD AND NECK SQUAMOUS-CELL CARCINOMA

被引:39
作者
WANG, MB
LICHTENSTEIN, A
MICKEL, RA
机构
[1] VET ADM MED CTR BRENTWOOD,DIV HEAD & NECK SURG,W112C,WILSHIRE & SAWTELLE BLVD,LOS ANGELES,CA 90073
[2] VET ADM MED CTR BRENTWOOD,DEPT MED,LOS ANGELES,CA 90073
[3] UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024
[4] VET ADM MED CTR BRENTWOOD,CTR CANC,LOS ANGELES,CA 90073
[5] VET ADM MED CTR BRENTWOOD,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90073
关键词
D O I
10.1177/019459989110500403
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Patients with head and neck squamous cell carcinomas (HNSCCs) manifest defects in cell-mediated immune function. Previous studies in this laboratory have demonstrated regional alterations in the immunocompetence of draining lymph nodes (LNs) in HNSCC patients. In this investigation, we studied functional activity of lymphocytes from lymph nodes in different locations in the radical neck dissections (RNDs) from patients undergoing operations for HNSCC. Lymphocytes from nodes close to the primary tumor ("near" lymph nodes or NLN) exhibited a significant decrease in interleukin-2 (IL-2)-activated cytotoxicity when compared to lymphocytes from distant nodes (-far" lymph nodes or FLN). In addition, co-culture experiments suggested the existence of a soluble regulatory factor, produced by lymph nodes, that inhibited the development of lymphokine-activated killer (LAK) cells in vitro. Further experiments with conditioned supernatants from the lymph node cells confirmed the presence of this soluble inhibitory factor. The inhibitory effect is significantly greater in NLNs than in FLNS. This hierarchical phenomenon suggests a regional network of immunosuppression in HNSCC patients. It is likely that tumor- and lymph node-induced suppression plays a role in limiting the efficacy of current immunotherapy protocols in human beings. A greater understanding of mechanisms of local inhibition of immune function will aid in improving adoptive immunotherapy for treatment of cancers in human beings.
引用
收藏
页码:517 / 527
页数:11
相关论文
共 33 条
[1]  
ALESSI DM, 1989, ARCH OTOLARYNGOL, V115, P725
[2]   EXCESSIVE PROSTAGLANDIN-E2 PRODUCTION BY SUPPRESSOR MONOCYTES IN HEAD AND NECK-CANCER PATIENTS [J].
BALCH, CM ;
DOUGHERTY, PA ;
TILDEN, AB .
ANNALS OF SURGERY, 1982, 196 (06) :645-650
[3]  
BERLINGER NT, 1984, LARYNGOSCOPE, V94, P1407
[4]  
BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
[5]  
BRUNNER KT, 1976, IN VITRO METHODS CEL, P423
[6]   IMMUNOLOGICAL ABNORMALITIES IN HEAD AND NECK CANCER [J].
EILBER, FR ;
MORTON, DL ;
KETCHAM, AS .
AMERICAN JOURNAL OF SURGERY, 1974, 128 (04) :534-538
[7]  
HOON DSB, 1987, CANCER RES, V47, P1740
[8]  
HOON DSB, 1987, CANCER RES, V47, P1529
[9]  
JENNRICH R, 1985, BMDP STATISTICAL SOF, P359
[10]   KINETIC-ANALYSIS OF THE INHIBITION OF NATURAL-KILLER (NK) ACTIVITY BY MULTIPLE POPULATIONS OF TUMOR-ACTIVATED SUPPRESSOR CELLS [J].
JOHNSON, DRE ;
POPE, BL .
IMMUNOBIOLOGY, 1986, 171 (03) :205-219